$GALDY News

Galderma Group AG (GALDY) Q3 2026 Sales/ Trading Statement Call - Slideshow

Galderma (SWX:GALD) Stock Could Be 39% Undervalued Following China Approval

Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines

Galderma raises 2026 sales growth outlook after Q3 revenue beats forecasts

Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance

AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis

Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering

New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing

Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older

30 Years of Restylane®: Reshaping the Aesthetics Field Through Science-Led, Patient-Centric Innovation

EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences

Why Galderma Group (SWX:GALD) Is Getting Attention Today

Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies

Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing

Galderma: Launch Investment Is Becoming An Earnings Engine

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping

Galderma Group AG 2026 Q2 - Results - Earnings Call Presentation

Galderma Group AG (GALDY) Q2 2026 Earnings Call Transcript